메뉴 건너뛰기




Volumn 4, Issue 5, 2012, Pages 614-622

Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling

Author keywords

Anti Her2 targeting; Ertumaxomab; Trifunctional antibody

Indexed keywords

CD3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERTUMAXOMAB; MITOGEN ACTIVATED PROTEIN KINASE 3; PERTUZUMAB; PROTEIN KINASE B; STAT3 PROTEIN; TRASTUZUMAB;

EID: 84866549256     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.21003     Document Type: Article
Times cited : (13)

References (46)
  • 1
    • 2142714017 scopus 로고    scopus 로고
    • Monoclonal antibodies as therapeutic agents for cancer
    • PMID:15120666
    • Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004; 5:292-302; PMID:15120666; http://dx.doi.org/10.1016/S1470-2045(04) 01467-6.
    • (2004) Lancet Oncol , vol.5 , pp. 292-302
    • Harris, M.1
  • 2
    • 84859140047 scopus 로고    scopus 로고
    • Improving treatment of HER2-positive cancers: Opportunities and challenges
    • doi:10.1126/scitranslmed.3001539
    • Stern HM. Improving treatment of HER2-positive cancers: opportunities and challenges. Sci Transl Med 2012; 4:127rv2. doi:10.1126/scitranslmed.3001539.
    • (2012) Sci Transl Med , vol.4
    • Stern, H.M.1
  • 3
    • 52949085848 scopus 로고    scopus 로고
    • Ertumaxomab: A trifunctional antibody for breast cancer treatment
    • PMID:18808314
    • Kiewe P, Thiel E. Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs 2008; 17:1553-8; PMID:18808314; http://dx.doi.org/10.1517/13543784.17.10.1553.
    • (2008) Expert Opin Investig Drugs , vol.17 , pp. 1553-1558
    • Kiewe, P.1    Thiel, E.2
  • 4
    • 33744803712 scopus 로고    scopus 로고
    • Phase I trial of the trifunctional anti- HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer
    • PMID:16707606
    • Kiewe P, Hasmüller S, Kahlert S, Heinrigs M, Rack B, Marmé A, et al. Phase I trial of the trifunctional anti- HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 2006; 12:3085-91; PMID:16707606; http://dx.doi.org/10.1158/1078-0432.CCR-05-2436.
    • (2006) Clin Cancer Res , vol.12 , pp. 3085-3091
    • Kiewe, P.1    Hasmüller, S.2    Kahlert, S.3    Heinrigs, M.4    Rack, B.5    Marmé, A.6
  • 5
    • 84873087647 scopus 로고    scopus 로고
    • Phase II study of single agent trifunctional antibody ertumaxomab (Anti-HER-2 & Anti-CD3) in HER-2 low expressing hormone-refractory advanced breast cancer patients (ABC)
    • Cardoso F, Dirix L, Conte PF, Semiglazov V, de Placido S, Jaeger M, et al. Phase II study of single agent trifunctional antibody ertumaxomab (Anti-HER-2 & Anti-CD3) in HER-2 low expressing hormone-refractory advanced breast cancer patients (ABC). San Antonio Breast Cancer Symposium 2010; P3-14-21.
    • (2010) San Antonio Breast Cancer Symposium
    • Cardoso, F.1    Dirix, L.2    Conte, P.F.3    Semiglazov, V.4    De Placido, S.5    Jaeger, M.6
  • 6
    • 66249126868 scopus 로고    scopus 로고
    • The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2
    • PMID:19435924
    • Jäger M, Schoberth A, Ruf P, Hess J, Lindhofer H. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res 2009; 69:4270-6; PMID:19435924; http://dx.doi.org/10.1158/0008-5472.CAN-08-2861.
    • (2009) Cancer Res , vol.69 , pp. 4270-4276
    • Jäger, M.1    Schoberth, A.2    Ruf, P.3    Hess, J.4    Lindhofer, H.5
  • 7
    • 0034051390 scopus 로고    scopus 로고
    • The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells
    • PMID:10901380
    • Zeidler R, Mysliwietz J, Csánady M, Walz A, Ziegler I, Schmitt B, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000; 83:261-6; PMID:10901380.
    • (2000) Br J Cancer , vol.83 , pp. 261-266
    • Zeidler, R.1    Mysliwietz, J.2    Csánady, M.3    Walz, A.4    Ziegler, I.5    Schmitt, B.6
  • 8
    • 60649122009 scopus 로고    scopus 로고
    • Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis
    • PMID:19216794
    • Ströhlein MA, Siegel R, Jäger M, Lindhofer H, Jauch KW, Heiss MM. Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 2009; 28:18; PMID:19216794; http://dx.doi.org/10.1186/1756-9966-28-18.
    • (2009) J Exp Clin Cancer Res , vol.28 , pp. 18
    • Ströhlein, M.A.1    Siegel, R.2    Jäger, M.3    Lindhofer, H.4    Jauch, K.W.5    Heiss, M.M.6
  • 9
    • 0032101894 scopus 로고    scopus 로고
    • EGF-induced redistribution of erbB2 on breast tumor cells: Flow and image cytometric energy transfer measurements
    • PMID:9627225
    • Nagy P, Bene L, Balázs M, Hyun WC, Lockett SJ, Chiang NY, et al. EGF-induced redistribution of erbB2 on breast tumor cells: flow and image cytometric energy transfer measurements. Cytometry 1998; 32:120- 31; PMID:9627225; http://dx.doi.org/10.1002/(SICI)1097-0320(19980601)32:2〈120:: AIDCYTO7〉3.0.CO;2-P.
    • (1998) Cytometry , vol.32 , pp. 120-131
    • Nagy, P.1    Bene, L.2    Balázs, M.3    Hyun, W.C.4    Lockett, S.J.5    Chiang, N.Y.6
  • 10
    • 47249112974 scopus 로고    scopus 로고
    • Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basis
    • PMID:18596360
    • Diermeier-Daucher S, Hasmann M, Brockhoff G. Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basis. Ann N Y Acad Sci 2008; 1130:280-6; PMID:18596360; http://dx.doi.org/10.1196/annals.1430.003.
    • (2008) Ann N Y Acad Sci , vol.1130 , pp. 280-286
    • Diermeier-Daucher, S.1    Hasmann, M.2    Brockhoff, G.3
  • 11
    • 0035256698 scopus 로고    scopus 로고
    • Untangling the Erb Bsignalling network
    • PMID:11252954
    • Yarden Y, Sliwkowski MX. Untangling the Erb Bsignalling network. Nat Rev Mol Cell Biol 2001; 2:127-37; PMID:11252954; http://dx.doi.org/10.1038/35052073.
    • (2001) Nat Rev Mol Cell Biol , vol.2 , pp. 127-137
    • Yarden, Y.1    Sliwkowski, M.X.2
  • 12
    • 83655196673 scopus 로고    scopus 로고
    • Novel monoclonal antibodies for cancer treatment: The trifunctional antibody catumaxomab (removab)
    • PMID:21716847
    • Seimetz D. Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab). J Cancer 2011; 2:309-16; PMID:21716847; http://dx.doi.org/10.7150/jca.2.309.
    • (2011) J Cancer , vol.2 , pp. 309-316
    • Seimetz, D.1
  • 13
    • 77953665930 scopus 로고    scopus 로고
    • Structural and functional characterization of the trifunctional antibody catumaxomab
    • PMID:20418662
    • Chelius D, Ruf P, Gruber P, Plöscher M, Liedtke R, Gansberger E, et al. Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs 2010; 2:309-19; PMID:20418662; http://dx.doi.org/10.4161/mabs. 2.3.11791.
    • (2010) MAbs , vol.2 , pp. 309-319
    • Chelius, D.1    Ruf, P.2    Gruber, P.3    Plöscher, M.4    Liedtke, R.5    Gansberger, E.6
  • 14
    • 84859409756 scopus 로고    scopus 로고
    • Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3
    • PMID:22248472
    • McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 2012; 11:582-93; PMID:22248472; http://dx.doi.org/10.1158/1535-7163.MCT-11- 0820.
    • (2012) Mol Cancer Ther , vol.11 , pp. 582-593
    • McDonagh, C.F.1    Huhalov, A.2    Harms, B.D.3    Adams, S.4    Paragas, V.5    Oyama, S.6
  • 15
    • 84859802154 scopus 로고    scopus 로고
    • Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose
    • PMID:22203367
    • Kamath AV, Lu D, Gupta P, Jin D, Xiang H, Wong A, et al. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. Cancer Chemother Pharmacol 2012; 69:1063-9; PMID:22203367; http://dx.doi.org/10.1007/ s00280-011-1806-6.
    • (2012) Cancer Chemother Pharmacol , vol.69 , pp. 1063-1069
    • Kamath, A.V.1    Lu, D.2    Gupta, P.3    Jin, D.4    Xiang, H.5    Wong, A.6
  • 16
    • 84855297353 scopus 로고    scopus 로고
    • Efficacy and safety of neoadjuvantpertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomisedmulticentre, openlabel, phase 2 trial
    • PMID:22153890
    • Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvantpertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomisedmulticentre, openlabel, phase 2 trial. Lancet Oncol 2012; 13:25-32; PMID:22153890; http://dx.doi.org/10.1016/S1470-2045(11)70336-9.
    • (2012) Lancet Oncol , vol.13 , pp. 25-32
    • Gianni, L.1    Pienkowski, T.2    Im, Y.H.3    Roman, L.4    Tseng, L.M.5    Liu, M.C.6
  • 17
    • 84862914692 scopus 로고    scopus 로고
    • Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
    • CLEOPATRA Study Group. PMID:22149875
    • Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al.; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366:109-19; PMID:22149875; http://dx.doi.org/10.1056/NEJMoa1113216.
    • (2012) N Engl J Med , vol.366 , pp. 109-119
    • Baselga, J.1    Cortés, J.2    Kim, S.B.3    Im, S.A.4    Hegg, R.5    Im, Y.H.6
  • 18
    • 79952276644 scopus 로고    scopus 로고
    • CLEOPATRA: A phase III evaluation of pertuzumab and trastuzumab for HER2- Positive metastatic breast cancer
    • PMID:21147694
    • Baselga J, Swain SM. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2- positive metastatic breast cancer. Clin Breast Cancer 2010; 10:489-91; PMID:21147694; http://dx.doi.org/10.3816/CBC.2010.n.065.
    • (2010) Clin Breast Cancer , vol.10 , pp. 489-491
    • Baselga, J.1    Swain, S.M.2
  • 19
    • 84856223809 scopus 로고    scopus 로고
    • Dual HER2-targeted approaches in HER2-positive breast cancer
    • PMID:21956210
    • Ahn ER, Vogel CL. Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Res Treat 2012; 131:371-83; PMID:21956210; http://dx.doi.org/10.1007/s10549-011-1781-y.
    • (2012) Breast Cancer Res Treat , vol.131 , pp. 371-383
    • Ahn, E.R.1    Vogel, C.L.2
  • 20
    • 73649149433 scopus 로고    scopus 로고
    • Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models
    • PMID:19934333
    • Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009; 69:9330-6; PMID:19934333; http://dx.doi.org/10.1158/0008-5472.CAN-08-4597.
    • (2009) Cancer Res , vol.69 , pp. 9330-9336
    • Scheuer, W.1    Friess, T.2    Burtscher, H.3    Bossenmaier, B.4    Endl, J.5    Hasmann, M.6
  • 21
    • 65349101151 scopus 로고    scopus 로고
    • Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941
    • PMID:19411071
    • Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009; 15:429-40; PMID:19411071; http://dx.doi.org/10.1016/j.ccr.2009.03.020.
    • (2009) Cancer Cell , vol.15 , pp. 429-440
    • Junttila, T.T.1    Akita, R.W.2    Parsons, K.3    Fields, C.4    Lewis Phillips, G.D.5    Friedman, L.S.6
  • 22
    • 19044380618 scopus 로고    scopus 로고
    • Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
    • PMID:12204533
    • Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2:127-37; PMID:12204533; http://dx.doi.org/10.1016/ S1535-6108(02)00097-1.
    • (2002) Cancer Cell , vol.2 , pp. 127-137
    • Agus, D.B.1    Akita, R.W.2    Fox, W.D.3    Lewis, G.D.4    Higgins, B.5    Pisacane, P.I.6
  • 23
    • 1942474587 scopus 로고    scopus 로고
    • The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
    • PMID:15059883
    • Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004; 64:2343-6; PMID:15059883; http://dx.doi.org/10.1158/0008-5472. CAN-03-3856.
    • (2004) Cancer Res , vol.64 , pp. 2343-2346
    • Nahta, R.1    Hung, M.C.2    Esteva, F.J.3
  • 24
    • 0030959114 scopus 로고    scopus 로고
    • A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors
    • PMID:9160890
    • Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y, Sela M. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 1997; 14:2099-109; PMID:9160890; http://dx.doi.org/10.1038/sj.onc.1201029.
    • (1997) Oncogene , vol.14 , pp. 2099-2109
    • Klapper, L.N.1    Vaisman, N.2    Hurwitz, E.3    Pinkas-Kramarski, R.4    Yarden, Y.5    Sela, M.6
  • 25
    • 0037434791 scopus 로고    scopus 로고
    • Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
    • PMID:12610629
    • Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr., et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421:756- 60; PMID:12610629; http://dx.doi.org/10. 1038/nature01392.
    • (2003) Nature , vol.421 , pp. 756-760
    • Cho, H.S.1    Mason, K.2    Ramyar, K.X.3    Stanley, A.M.4    Gabelli, S.B.5    Denney Jr., D.W.6
  • 26
    • 1842605531 scopus 로고    scopus 로고
    • Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
    • PMID:15093539
    • Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5:317-28; PMID:15093539; http://dx.doi.org/10.1016/S1535- 6108(04)00083-2.
    • (2004) Cancer Cell , vol.5 , pp. 317-328
    • Franklin, M.C.1    Carey, K.D.2    Vajdos, F.F.3    Leahy, D.J.4    De Vos, A.M.5    Sliwkowski, M.X.6
  • 27
    • 14644392200 scopus 로고    scopus 로고
    • Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation
    • PMID:15748904
    • Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllosi J, Brockhoff G. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 2005; 304:604-19; PMID:15748904; http://dx.doi.org/10.1016/j.yexcr.2004.12.008.
    • (2005) Exp Cell Res , vol.304 , pp. 604-619
    • Diermeier, S.1    Horváth, G.2    Knuechel-Clarke, R.3    Hofstaedter, F.4    Szöllosi, J.5    Brockhoff, G.6
  • 29
    • 33646739287 scopus 로고    scopus 로고
    • Effects of HER2-binding affibody molecules on intracellular signaling pathways
    • PMID:16651854
    • Ekerljung L, Steffen AC, Carlsson J, Lennartsson J. Effects of HER2-binding affibody molecules on intracellular signaling pathways. Tumour Biol 2006; 27:201-10; PMID:16651854; http://dx.doi.org/10.1159/000093023.
    • (2006) Tumour Biol , vol.27 , pp. 201-210
    • Ekerljung, L.1    Steffen, A.C.2    Carlsson, J.3    Lennartsson, J.4
  • 30
    • 0033392493 scopus 로고    scopus 로고
    • Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1
    • PMID:10635327
    • Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 1999; 4:1029-40; PMID:10635327; http://dx.doi.org/10.1016/S1097-2765(00)80231-2.
    • (1999) Mol Cell , vol.4 , pp. 1029-1040
    • Levkowitz, G.1    Waterman, H.2    Ettenberg, S.A.3    Katz, M.4    Tsygankov, A.Y.5    Alroy, I.6
  • 31
    • 0032512841 scopus 로고    scopus 로고
    • Csk homologous kinase, a novel signaling molecule, directly associates with the activated ErbB-2 receptor in breast cancer cells and inhibits their proliferation
    • PMID:9461599
    • Zrihan-Licht S, Deng B, Yarden Y, McShan G, Keydar I, Avraham H. Csk homologous kinase, a novel signaling molecule, directly associates with the activated ErbB-2 receptor in breast cancer cells and inhibits their proliferation. J Biol Chem 1998; 273:4065-72; PMID:9461599; http://dx.doi.org/ 10.1074/jbc.273.7.4065.
    • (1998) J Biol Chem , vol.273 , pp. 4065-4072
    • Zrihan-Licht, S.1    Deng, B.2    Yarden, Y.3    McShan, G.4    Keydar, I.5    Avraham, H.6
  • 32
    • 0030794283 scopus 로고    scopus 로고
    • Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation
    • PMID:9271418
    • Dankort DL, Wang Z, Blackmore V, Moran MF, Muller WJ. Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation. Mol Cell Biol 1997; 17:5410-25; PMID:9271418.
    • (1997) Mol Cell Biol , vol.17 , pp. 5410-5425
    • Dankort, D.L.1    Wang, Z.2    Blackmore, V.3    Moran, M.F.4    Muller, W.J.5
  • 34
    • 0032482368 scopus 로고    scopus 로고
    • Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential
    • PMID:9671404
    • Zhang HT, O'Rourke DM, Zhao H, Murali R, Mikami Y, Davis JG, et al. Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential. Oncogene 1998; 16:2835-42; PMID:9671404; http://dx.doi.org/10.1038/sj.onc.1201820.
    • (1998) Oncogene , vol.16 , pp. 2835-2842
    • Zhang, H.T.1    O'Rourke, D.M.2    Zhao, H.3    Murali, R.4    Mikami, Y.5    Davis, J.G.6
  • 35
    • 33845804718 scopus 로고    scopus 로고
    • Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity
    • PMID:17030621
    • Xu W, Yuan X, Beebe K, Xiang Z, Neckers L. Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity. Mol Cell Biol 2007; 27:220-8; PMID:17030621; http://dx.doi.org/10.1128/MCB.00899-06.
    • (2007) Mol Cell Biol , vol.27 , pp. 220-228
    • Xu, W.1    Yuan, X.2    Beebe, K.3    Xiang, Z.4    Neckers, L.5
  • 37
    • 79952741743 scopus 로고    scopus 로고
    • Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors
    • PMID:21406401
    • Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, et al. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res 2011; 71:2250-9; PMID:21406401; http://dx.doi.org/10.1158/0008-5472.CAN-10-2277.
    • (2011) Cancer Res , vol.71 , pp. 2250-2259
    • Rudnick, S.I.1    Lou, J.2    Shaller, C.C.3    Tang, Y.4    Klein-Szanto, A.J.5    Weiner, L.M.6
  • 38
    • 0032895235 scopus 로고    scopus 로고
    • Trastuzumab, a recombinant DNAderived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer
    • PMID:10211534
    • Goldenberg MM. Trastuzumab, a recombinant DNAderived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999; 21:309-18; PMID:10211534; http://dx.doi.org/10.1016/S0149-2918(00) 88288-0.
    • (1999) Clin Ther , vol.21 , pp. 309-318
    • Goldenberg, M.M.1
  • 39
    • 0033953634 scopus 로고    scopus 로고
    • Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo
    • PMID:10657127
    • Park BW, Zhang HT, Wu C, Berezov A, Zhang X, Dua R, et al. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat Biotechnol 2000; 18:194-8; PMID:10657127; http://dx.doi.org/10.1038/72651.
    • (2000) Nat Biotechnol , vol.18 , pp. 194-198
    • Park, B.W.1    Zhang, H.T.2    Wu, C.3    Berezov, A.4    Zhang, X.5    Dua, R.6
  • 40
    • 84856034032 scopus 로고    scopus 로고
    • Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment
    • PMID:22126733
    • Schroeder P, Lindemann C, Dettmar K, Brieger J, Gosepath J, Pogorzelski B, et al. Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment. Clin Transl Oncol 2011; 13:889-98; PMID:22126733; http://dx.doi.org/10.1007/s12094-011-0751-5.
    • (2011) Clin Transl Oncol , vol.13 , pp. 889-898
    • Schroeder, P.1    Lindemann, C.2    Dettmar, K.3    Brieger, J.4    Gosepath, J.5    Pogorzelski, B.6
  • 41
    • 0035889129 scopus 로고    scopus 로고
    • Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
    • PMID:11588051
    • Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001; 98:2526-34; PMID:11588051; http://dx.doi.org/10.1182/blood.V98.8.2526.
    • (2001) Blood , vol.98 , pp. 2526-2534
    • Ruf, P.1    Lindhofer, H.2
  • 42
    • 47149094444 scopus 로고    scopus 로고
    • Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctionalbispecific antibody
    • PMID:18495330
    • Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Ruf P, Slavin S. Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctionalbispecific antibody. Exp Hematol 2008; 36:997-1003; PMID:18495330; http://dx.doi.org/10.1016/j.exphem.2008.03.005.
    • (2008) Exp Hematol , vol.36 , pp. 997-1003
    • Morecki, S.1    Lindhofer, H.2    Yacovlev, E.3    Gelfand, Y.4    Ruf, P.5    Slavin, S.6
  • 43
    • 34447336165 scopus 로고    scopus 로고
    • Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation
    • PMID:17635517
    • Brockhoff G, Heckel B, Schmidt-Bruecken E, Plander M, Hofstaedter F, Vollmann A, et al. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif 2007; 40:488-507; PMID:17635517; http://dx.doi.org/10.1111/j.1365-2184.2007.00449.x.
    • (2007) Cell Prolif , vol.40 , pp. 488-507
    • Brockhoff, G.1    Heckel, B.2    Schmidt-Bruecken, E.3    Plander, M.4    Hofstaedter, F.5    Vollmann, A.6
  • 44
    • 0021273333 scopus 로고
    • Flow cytometric measurement of fluorescence resonance energy transfer on cell surfaces. Quantitative evaluation of the transfer efficiency on a cell-by-cell basis
    • PMID:6428482
    • Trón L, Szöllósi J, Damjanovich S, Helliwell SH, Arndt-Jovin DJ, Jovin TM. Flow cytometric measurement of fluorescence resonance energy transfer on cell surfaces. Quantitative evaluation of the transfer efficiency on a cell-by-cell basis. Biophys J 1984; 45:939- 46; PMID:6428482; http://dx.doi.org/10.1016/S0006-3495(84)84240-X.
    • (1984) Biophys J , vol.45 , pp. 939-946
    • Trón, L.1    Szöllósi, J.2    Damjanovich, S.3    Helliwell, S.H.4    Arndt-Jovin, D.J.5    Jovin, T.M.6
  • 45
    • 3242784810 scopus 로고    scopus 로고
    • Computer program for determining fluorescence resonance energy transfer efficiency from flow cytometric data on a cell-by-cell basis
    • PMID:15265619
    • Szentesi G, Horváth G, Bori I, Vámosi G, Szöllosi J, Gáspár R, et al. Computer program for determining fluorescence resonance energy transfer efficiency from flow cytometric data on a cell-by-cell basis. Comput Methods Programs Biomed 2004; 75:201-11; PMID:15265619; http://dx.doi.org/10.1016/j.cmpb.2004.02.004.
    • (2004) Comput Methods Programs Biomed , vol.75 , pp. 201-211
    • Szentesi, G.1    Horváth, G.2    Bori, I.3    Vámosi, G.4    Szöllosi, J.5    Gáspár, R.6
  • 46
    • 44149098849 scopus 로고    scopus 로고
    • Cytogenetic analysis of HER1/ EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
    • PMID:18182100
    • Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S, et al. Cytogenetic analysis of HER1/ EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res 2008; 10:R2; PMID:18182100; http://dx.doi.org/10. 1186/bcr1843.
    • (2008) Breast Cancer Res , vol.10
    • Sassen, A.1    Rochon, J.2    Wild, P.3    Hartmann, A.4    Hofstaedter, F.5    Schwarz, S.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.